There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

Sprenger Healthcare Elms Retirement Village is accepting sign-ups for a Take Control with Total Parkinson’s exercise class ...

Leading neurologists and movement disorder specialists have made submissions to the Australian chemical regulator calling for a ban on paraquat, over its links with Parkinson's disease.

“Genetic variants associated with larger brain volumes in key brain regions also increase the risk of Parkinson’s disease, while variants linked to smaller brain volumes in key regions are ...

Parkinson’s disease (PD ... In some cases, these can potentially slow disease progression. Studies show that moderate to vigorous cardiovascular exercise can slow disease progression ...

The process of diagnosis for someone dealing with symptoms of Parkinson’s disease can sometimes leave the patient and even their healthcare provider frustrated due to the slow pace of assessment and ...

aDivision of Neurology, Department of Medicine, and The Mah Pooi Soo & Tan Chin Nam Centre for Parkinson's & Related Disorders, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia ...

The U.S. FDA has approved a 24-hour continuous subcutaneous infusion for adults with advanced Parkinson’s disease (PD). This therapy is the first of its kind, designed to address motor fluctuations ...

Oct. 18, 2024 -- The FDA has approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa). This new option is designed to help people ...

Vyalev combines foscarbidopa, a prodrug of carbidopa, and foslevodopa, a prodrug of levodopa, into a solution for continuous subcutaneous 24-hour infusion. The Food and Drug Administration (FDA ...

it is crucial to prioritise primary outcomes that are relevant and understandable for patients The number of patients with Parkinson’s disease is increasing, and so is the complexity and variety of ...

as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). Developed by US pharma major ...